MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading

Director Lucier purchased 100,000 shares across 2 transactions for $368,544.16 (+181.4% increase in holdings)

Gregory T. Lucier, a Director at Maravai LifeSciences, executed 2 separate open-market purchases totaling 100,000 shares for $368,544.16 at prices of $3.70 and $3.67, increasing his holdings from 55,123 shares to 155,123 shares (+181.4%). The company operates under a challenging backdrop: revenue declined -10.3% year-over-year, net income was $-25,556,000.00 in the latest full fiscal year, and the current share price of $3.69 sits -39.8% below the 52-week high, though it has risen +28.6% in the past 30 days. Lucier's cross-ticker track record shows 6 prior open-market purchases with a 33.33% 90-day win rate and average 90-day return of -0.7%, providing limited statistical confidence in his timing. The magnitude of this purchase relative to his prior holdings is substantial, but the company's profitability challenges and the director's modest historical accuracy create divergent signals for investors to evaluate.

CEO Bernd Brust buys 216,212 shares at $3.25 amid three consecutive days of purchases; stock down -45.5% from 52-week high amid unprofitable fundamentals.

Brust Bernd, Chief Executive Officer, purchased 216,212 shares of MRVI at $3.25 on 2025-11-13, increasing his holdings to 466,771 shares (an 86.3% increase from 250,559 shares). This transaction is part of a three-day buying pattern: he also purchased shares on 2025-11-12 and 2025-11-11, suggesting a deliberate accumulation sequence. The stock is trading at $3.34, down -45.5% from its 52-week high of $6.13. Fundamentally, the company is unprofitable with negative net income of $-25,556,000 in the latest quarter and negative full-year net income, combined with annual revenue decline of -10.3%. The three consecutive insider purchases against a deteriorating financial backdrop and heavily depressed valuation warrant attention to whether the CEO's accumulation reflects internal conviction about near-term recovery or repositioning in a distressed capital structure.

MRVI CEO Brust Bernd purchases 250,559 shares in 2 transactions (Nov 11-12) for $809,010.42; major personal stake from zero prior holdings amid -47.0% from 52-week high.

Brust Bernd, Chief Executive Officer of Maravai LifeSciences, made 2 separate purchases totaling 250,559 (250.6K shares) for $809,010.42 between November 11-12 at a blended average price of $3.23, establishing a first material equity position in the stock. The timing occurs with the stock trading 47.0% below its 52-week high of $6.13, in a company that reported -$25,556,000.00 (-$25.6M) net income in the latest quarter with annual revenue declining -10.3% year-over-year. The CEO's accumulation of a 250.6K share position from zero holdings represents a significant personal commitment, occurring while the company faces negative profitability and revenue headwinds that require scrutiny against the purchase rationale and forward-looking guidance.

Director DeFord John A bought 17,500 MRVI shares at $5.75 (+33.3% to holdings) amid -67.3% revenue decline and -$99.0M net loss.

Director John A DeFord acquired 17,500 shares for $100,625.00, increasing his holdings by 33.3% from 52,546 to 70,046 shares, at a transaction price of $5.75. This purchase occurs in a context of severe deterioration: the company reported a -67.3% annual revenue decline and a full-year net loss of -$99,038,000.00, with the stock down -54.1% from its 52-week high of $11.34 and -46.3% over the trailing 90-day period. The director's substantial accumulation during a period of quantifiable financial distress and sharp stock declines invites scrutiny into whether this represents conviction in a recovery or reflects other motivations; the scale of the increase in his personal holdings warrants monitoring of subsequent filings to establish any discernible pattern.

MRVI insider Carl Hull purchases 175,000 shares at $5.64 amid -67.3% revenue decline and $-99.0M loss

Insider Carl Hull acquired 175,000 shares of MARAVAI LIFESCIENCES (MRVI) at $5.64, establishing an initial position. The acquisition occurs against a backdrop of severe operational deterioration: annual revenue contracted -67.3% and the company reported a full-year net loss of $-99.0M, with the latest quarterly revenue standing at $65.2M. The stock has declined significantly—trading at $5.70 today, down -49.7% from its 52-week high of $11.34 and -28.8% over the past 30 days. Hull's entry represents a discrete purchase of a previously unowned position at depressed price levels relative to historical trading range, occurring during a period of material financial stress and negative momentum.